April 25, 2025
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA) provides an update on the Annual General Meeting 2025 which has been convened on March 24, 2025 (AGM).
As previously announced, the AGM agenda includes the proposal to appoint Mr Bob White (American, 1962) as a new member of the Supervisory Board, with effect from May 8, 2025, given his extensive expertise and experience in health technology and quality.
Since the company published the agenda for the AGM, Mr White has been nominated to become Chief Executive Officer at Olympus Corporation and has informed the company that in view of this nomination and his nomination at Philips, he will step down from other board positions he currently holds.
In light hereof, the Supervisory Board and Mr White have agreed that he will become a member of Philips’ Quality & Regulatory (Q&R) Committee but that he will not be acting as its chair as was previously communicated.
Following shareholders’ approval of all proposals in respect of the Supervisory Board composition at the AGM, Dr Paul Stoffels will become chair of the Q&R Committee of the Supervisory Board, and Mrs Herna Verhagen will succeed Dr Paul Stoffels as chair of its Remuneration Committee.
Following his appointments at Philips and Olympus, Mr White will hold one non-executive and one executive position at publicly listed companies in line with current guidelines from proxy advisors on directors’ external commitments.
For further information, please contact:
Michael Fuchs
Philips Global External Relations
Tel.: +31 61486 9261
E-mail: media@philips.com
Dorin Danu
Philips Investor Relations
Tel.: +31 20 59 77055
E-mail: dorin.danu@philips.com
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.
Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,800 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
Forward-looking statements and other important information
This release contains certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about the strategy, estimates of sales growth, future EBITA, future developments in Philips’ organic business and the completion of acquisitions and divestments. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.
-
TUMI 50周年金色限量系列登场每件作品皆为时间的艺术,19Degree限量编号致敬非凡旅程 纽约2025年4月25日 /美通社/ -- 今日,国际旅行和生活方式品牌TUMI途明发布50周年限量金色胶囊系列,包含行2025-04-25
-
阿布扎比举办“医疗保健行业领袖”圆桌会议-阿布扎比举办“医疗保健行业领袖”圆桌会议,领导落实合作策略,为医疗保健领域打造负责任的人工智能 在阿布扎比全球健康周期间举行的圆桌会议将全球健康领域领2025-04-25
-
奇瑞LEPAS全球首发:以优雅科技重塑未来出行生态芜湖2025年4月25日 /美通社/ -- 4月24日,奇瑞正式发布全新品牌LEPAS,并携首款车型L8完成全球首秀。发布会以"添彩 驾驭"为主题,吸引了全球800余家核心经销商及头部2025-04-25
-
艾棣维欣(NEEQ: 874055)发布2024年度报告苏州2025年4月25日 /美通社/ -- 4月25日,创新疫苗及药物企业苏州艾棣维欣生物技术股份公司披露2024年度报告。报告显示,2024年公司业务稳步推进,在可溶性微针递送领2025-04-25
-
君实生物宣布特瑞普利单抗一线治疗黑色素瘤在中国获批上海2025年4月25日 /美通社/ -- 北京时间2025年4月25日,君实生物(1877.HK,688180.SH)宣布,由公司自主研发的抗PD-1单抗药物特瑞普利单抗注射液(拓益®)用于不可切除或转2025-04-25